The first two authors contributed equally to this work (+)-2-(1-hydroxyl-4-oxocyclohexyl) ethyl caffeate (HOEC) was isolated from Incarvillea matret var. granditlora (Wehrhahn) Grierson. The plants of the Incarvillea genus have long been used as folk medicines for the treatment of inflammation-related diseases in China. 5-Lipoxygenase (5-LOX), a key enzyme in the arachidonic acid (AA) cascade, was identified as a potential target of HOEC by a pulldown assay, and then extensively validated by biosensor-based affinity detection, enzyme-based activity assays, cell-based AA metabolite analysis and computer-aided AA network simulation. Further in vivo studies of AA-induced ear oedema, ovalbumin (OVA)-induced lung inflammation and collagen-induced arthritis demonstrated the anti-inflammatory potency and validated the therapeutic target of HOEC. This work revealed that HOEC acted as an anti-inflammatory agent targeting 5-LOX, which not only confirmed the key role of 5-LOX in inflammation but also provided a paradigm for the exploration of natural product mechanisms of action.
lack of integration of these techniques limits further application of new techniques. New strategies for identifying the targets and mechanism investigation of small molecules are emerging, which is reflected by the use of integrated techniques for these studies (5, 6) . 5 -Lipoxygenase (5-LOX) IS a focus of inflammation research because It IS an important rate-limiting enzyme for leukotriene B 4 (LTB 4 ) synthesis in the arachidonic acid (AA) pathway (7, 8) . 5-LOX has long been considered to play key roles in the pathogenesis of inflammatory and immune disorders, such as asthma, arthritis, and cancer (9, 10) . Recent reports suggest a close relationship between 5-LOX and atherosclerosis and gout (11, 12) . Inhibition of 5-LOX activity and the production of its product LTB 4 , in these diseases can have beneficial effects. Developing LTB 4 receptor antagonists and 5-LOX inhibitors are two effective strategies for targeting this pathway (13) . Several 5-LOX inhibitors have been reported in preclinical or clinical studies (8, 13) , Zileuton is the only clinically available 5-LOX inhibitor and is used for the maintenance treatment of asthma (14) . According to Food and Drug Administration (FDA)-approved guidelines, serious hepatotoxicity and neuropsychiatric events may occur, which has hampered further clinical applications of Zileuton (15) . Therefore, searching for new 5-LOX inhibitors is of great clinical significance for the treatment of inflammatory diseases, cancer and cardiovascular disease.
Inflammation, the fundamental mechanism in reactions to internal and external mjunes or pathogens, can be classified as either acute or chronic depending on the disease duration. Acute inflammation is caused by vascular permeability and the accumulation of inflammatory mediators. AA or phorbol 12-myristate 13-acetate (PMA)-induced ear oedema, zymosan-induced peritonitis, and plateletactivating factor (PAF)-induced systemic shock are representative acute in vivo inflammatory models, in which the role of 5-LOX has been confirmed (16, 17) . Persistent acute inflammation or autoimmune reactions often result in chronic inflammation. Aside from the involvement of eicosanoid accumulation, inflammatory cell infiltration and vascular permeability enhancement, the characteristic imbalance of specific humoral and cellular immune responses also contributes to the development of various chronic inflammations such as allergic asthma and autoimmune rheumatoid arthritis. The important roles of 5-LOX in these disorders have been reported by numerous studies (8, 16, 17) .
(+)-2-( I-hydroxyl-4-oxocyclohexyl) ethyl caffeate (HOEC), a caffeic ester, was isolated as a major constituent from Incarvillea mairei var. granditlora (Wehrhahn) Grierson. The plants of the Incarvillea genus have long been used as folk medicines in the south and southwest of China and have anti-inflammatory properties, such as heat-clearing, detoxification and wind dampness-dispelling (18) . To our knowledge, no pharmacological bioactivity or therapeutic target has been reported for HOEC.
In this study, we used a deliberate strategy to investigate the activity and potential target ofHOEC. To identify the potential target ofHOEC, we logically integrated pull-down assays, the surface acoustic wave (SAW) technique, BioLayer interferometry (BLI), in vitro pure enzyme-and cell-based assays. Further validation of the target was performed in diverse acute and chronic inflammations, including AA-induced ear oedema, OVA-induced lung inflammation and collagen-induced arthritis. This study highlights the reliability and effectiveness of a chemical biology approach, which is a promising paradigm for target identification and elucidating the mechanism of small molecules in drug research.
MATERIALS AND METHODS

Compound Source
(+)-2-(1-hydroxyl-4-oxocyclohexyl) ethyl caffeate (HOEC) is a naturally occurring caffeic ester isolated from the whole plants of Incarvillea mairei var. granditlora (Wehrhahn) Grierson (19) . The chemical structure is shown in Fig. I . HOEC used in the present study was synthesised according to the procedure reported by our laboratory (20) . The purity of the synthetic HOEC was assessed by HPLC and found to be greater than 97%.
Animals
ICR mice (male, 18-22 g), C57BL/6 mice (female, 18-22 g), Sprague-Dawley rats (male, 180-200 g), and Wistar rats (male, 130-150 g) were purchased from the Shanghai SLAC Laboratory Animal Co., LTD (Shanghai, China).
OH
Biosensor-based affinity analyses
Biosensor-based affinity analyses, including surface In vitro pure enzyme assay Effects of HOEC on the enzyme activities of 5-LOX, 15-LOX, LTA 4H and COX-I/2 were determined. Details regarding the procedure used in our laboratory have been previously reported (22) .
Macrophage-based assay ofAA metabolites
Effects of HOEC on AA metabolites (LTB 4 , 5, 8, II, 12, 15-HETE, PGE 2 , TXB 2 , 12-HHT) in rat peritoneal macrophages were determined using mass spectrometry. The procedure was detailed in our previous paper (22) .
Dynamic simulation profiling ofthe AA metabolic network
A mathematical model was established according to Yang's reports (23, 24) to dynamically simulate the activity of HOEC on the AA metabolic network. Enzymatic reactions and feedback loops in the AA metabolic network were monitored using a series of ordinary differential equations (ODEs). The ODEs were solved using the odel5s routine of Matlab 7.0 (Mathworks, http://www. mathworks.com). The activity of HOEC against the five enzymes in the AA metabolic network was defined as the ratio of drug concentration to inhibition constant ([1] / Ki). acoustic wave (SAW) and BioLayer interferometry (BLI) assays, were applied to investigate the direct binding of HOEC to immobilised human recombinant 5-LOX. An S-sens-K5Biosensor instrument (SAW Instruments, Bonn, Germany) equipped with a SAW biosensor chip surface was used for the SAW experiment, in which mass loading alterations obtained from biomolecular interaction processes on the surface ofthe sensor chip resulted in phase changes of the surface acoustic waves (21) . The 5-LOX enzyme (20 11M, human, Cayman, USA) was immobilised on the SAW biosensor chip surface. carbonic anhydrase (CA) II was used as the negative control to eliminate nonspecific binding. Increasing concentrations of HOEC in running buffer (PBS with 0.5% DMSO, pH 7.4) were subsequently injected. The specific binding curves and kinetic constants (K D , knn and knIT) were obtained.
The BioLayer interferometry (BLI) technique was used and the results were compared with the SAW biosensor data. 5-LOX and HOEC were prepared as previously described. An Octet RED96 instrument (Forteflio Octet QK) equipped with a super streptavidin sensor chip was applied to the test. The specific binding profile was generated and equilibrium constants (K D , kon and k nn.) were calculated from these data.
LTB 4 and PGE2formation in human whole blood
Whole blood from healthy volunteers was heparinised and aliquoted. After preincubation with various concentrations ofHOEC or the vehicle for 5 min at 37°C,
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Animals were housed in standard pathogen-free cages in a climate-controlled environment with a 12-hr light! 12-hr dark cycle. Sterile food and water were naturally provided. All procedures were conducted in accordance with the Guidelines for Care and Use of Laboratory Animals of the Second Military Medical University and government. o
Pull-down assay
An ex vivo pull down assay was performed to determine the potential target proteins of HOEC. HOEC was coupled to CNBr-activated Sepharose 4B beads by incubating 5 mg ofHOEC with 0.3 g of beads in coupling buffer (0.1 M NaHC0 3 pH 8.3, 0.5 M NaCI containing 40% DMSO) overnight at 4°C with gentle rocking. After washing with coupling buffer and blocking with Tris-HCI buffer (0.1 M, pH 8.0), HOEC-Sepharose 4B beads were incubated with rat macrophage Iysates in reaction buffer (50 mM Tris, 5 mM EDTA, 150 mM NaCl, 1 mM DTT, 0.01% NP40, 2 ug/ml. bovine serum albumin, 0.02 mM phenylmethylsulfonyl fluoride and I% protease inhibitor, pH7.5), after overnight incubation, the beads were washed with Tris buffer (50 mM Tris, 5 mM EDTA, 150 mM NaCl, I mM DTT, 0.01% NP40 and 0.02 mM PMSF, pH 7.5). Proteins bound to the beads were eluted with 0.1 M phosphate-buffered saline (PBS, pH 7.4) and separated by SDS-PAGE (4%-12% gradient gels, Invitrogen). The bound proteins were analysed by mass spectrometry. Western blotting was used to detect 5-LOX in rat macrophage Iysates with an anti-5-LOX antibody (I :500 dilution, Abeam Ltd., Hong Kong) the blood was stimulated with the calcium ionophore A23l87 (5 11M) for 15 min. The reaction was terminated by freezing. After centrifugation, the supernatant was collected for the measurement ofLTB 4 
and PGE 2 •
Apoptosis assay
Cells were incubated with HaEC or the vehicle for 24 h, and then stained with annexin V-FITC and PI to quantify the apoptotic cells by flow cytometry.
AA-induced mouse ear oedema
ICR mice were treated on the inner surfaces ofthe right ears with 20 ul, of drug for 20 minutes. Then, the right ears were stimulated with AA (2 mg/ear, in acetone) on the outer surfaces, and the left ears were treated with the vehicle. One hour later, 6 mm-diameter disc ear biopsies were collected. The extent of oedema was assessed by determining the weight difference between the right ear (inflamed) and the left ear (non-inflamed).
LTB 4formation in oedematous ears
To detect LTB 4 , ear biopsies were ground into a powder in a liquid nitrogen bath, and then homogenised in PBS (pH 7.0) containing 1% PMSF. The homogenates were centrifuged and the supernatants were collected. LTB 4 in the supernatants was measured using enzymelinked immunosorbent assay (ELISA).
Vascularpermeability assay
To measure vascular permeability changes, mice were intravenously injected with 0.5% Evans blue dye solution (10 mL/kg of body weight) 1 h before the ear oedema experiment. Ear biopsies were incubated in 1 mL of formamide at 55°C for 24 h and the extracts were analysed by spectrophotometry at 610 nm.
OVA-induced mouse lung inflammation
Female C57BL/6 mice were intraperitoneally sensitised, intraperitoneally boosted, and intranasally challenged with OVA(10 I1g, Sigma) in alum as described in Fig. 2 . Mice were intraperitoneally injected with HaEC (1 or 0.2 mg/kg) once daily from day 15 to 20. Zileuton was used as a reference treatment (10 mg/kg, i.g.). Blood, bronchoalveolar lavage (BAL) fluid and lung tissue were collected on day 21. The lavage samples were used for cell counting and LTB 4 analysis. Plasma was collected for IgE and LTB 4 assays and lung tissue was collected for histological study.
Collagen-induced rat arthritis (CIA) Induction and assessment ofCIA
Wistar rats were dermally sensitised and dermally boosted with bovine type-II collagen (CIl), (Chondrex, Inc., Redmond, WA) in incomplete Freund's adjuvant as described in Fig. 3 . HaEC (1 or 0.2 mg/kg) was administered i.p. to the rats once daily from day 1 to 28. Zileuton was used as a reference (10 mg/kg, i.g,). Clinical score, incidence and body weight were monitored every two days from day 12 to 28. The clinical score was calculated according to the previous report (25) . Blood and leg samples were prepared on day 28. . Experimental Procedure f or Collagen-induced Arthritis (CIA). Male Wistar rats were dermally sensitised and boosted with type-II collagen in incomplete Freund's adjuvant. Rats were treated once daily from day 1 to 28. Clinical score, incidence, and body weight were monitored every two days from day 12 to 28. Sacrifice was performed on day 28.
OVA immunization OVA nebulization (20 min/d) Sacrifice
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Biochemical detection
Plates coated with CII (5 ug/ml) were used to determine IgG (lgG I, IgG2a, IgG2b) and IgM antibodies in plasma by ELISA. Antibodie s were obtained from Southern Biotechnology Associates Inc. (Birmingham , USA). AA metabolites (LTB 4 and PGE 2 ) were quantified in blood plasma and joint homogenate. ELISA kits were from Cayman Chemicals (Ann Arbour, MI, USA).
5-LOX mRNA expression in joint tissues was quantified using the real-time SYBR green PCR method. Reagents were purchased from Takara (Tokyo, Japan) . Target mRNA expression was normalised using p-actin and quantified with the 2· M Ct method. Primer sequences used were as follows: p-actin forward: 5' -CCGCCCTAGGCACCAGGGT-3 ', p-actin reverse: 5' -GGCTGGGGTGTTGAAGGTCTCAAA-3 '; 5-LOX forward:
5'-ACCCCCTTITCAAGCTGCTGG-3 ', 5-LOX reverse: 5'-CGGCAATCA CGCTG ACGATG -3'.
Protein expression was analysed by western blotting with the anti-5-LOX antibody. The secondary antibody, IRDye 800CW (1:15000, LI-COR Biosciences, Lincoln, NE, USA), and the Odyssey infrared imaging system (LI-COR) were used to visualise the protein bands. The relative amount of protein was calculated by comparing the optical intensity of the target protein band to that of p-actin.
Histological and radiographic analysis
Removed legs were fixed, decalcified, and
Hematoxylin-and Eosin-stained (H&E) stained . Histological features were determined by microscopic examination. As for Micro-computer tomography (CT) assay, legs were excised from the surrounding soft tissues and fixed in formalin. Micro-CT was performed as previous described (26) .
Statistical analysis
Data were analysed by one-way analysis of variance (ANOVA) followed by Dunnett's test or a Kruskal-Wallis ANOVA on Ranks followed by Dunn's test for multiple comparisons and expressed as the means ± S.E.M. The concentration at which 50% inhibition occurred (lC so ) was calculated by the median-effect equation ." P< 0.05 was considered a significant difference.
RESULTS
Identification of5-LOX as a HOEC-bound protein
To determine the potential biological target proteins of HOEC, an ex vivo pull-down assay using HOEC-conjugated Sepharose 4B beads was performed. A band of approximately 75 kDa was detected by SDS-PAGE when HOEC-Sepharose 4B beads were used for the pull-down, but not with unmodified Sepharose 4B beads (Fig. 4A ). Mass spectrometric analysis ofthe band yielded29 proteins. Among them, 25 proteins were successfully identified and categorised using Gene Ontology (GO) (Fig. 4B ). Most of these binding proteins were cell structurerelated proteins and basal functional proteins (i.e., cytoskeletal proteins, metabolic proteins, and binding proteins). Excitingly, arachidonate 5-lipoxygenase (5-LOX), which is involved in the pathogenesis of inflammation, was detected in the band. Western blotting also demonstrated that 5-LOX was one ofthe macrophage proteins that bound to HOEC (Fig. 4C,  top) . Further pull-down assays using recombinant 5-LOX confirmed the specific binding of HOEC to 5-LOX (Fig. 4C, bottom) .
Biosensor-based affinity analysis
To monitor the biomolecular interaction ofHOEC with 5-LOX, biosensor-based affinity analysis was performed using the SAW technique. In the present experiment, the phase shift represents the mass of adsorbed material on the 5-LOX-coated sensor. The overlay phase curves were obtained by injection of increasing concentrations ofHOEC after subtracting the phase signal from the negative control CA II. The data revealed that the resulting positive phase shift was due to the increase in mass loading of HOEC from biomolecular interaction processes (Fig. 4D ). Based on the SAW data, the interaction was reanalysed using BioLayer interferometry (BLI), a simple platform that enables label-free monitoring of biomolecular interactions (27) . Similarly, a concentration-dependent binding profile of HOEC and 5-LOX was observed. The qualitative data (K D , k on ' k off ) we obtained were close to the SAW data ( Fig. 4E ). Accordingly, these results clearly determined that 5-LOX was specifically bound to HOEC, suggesting that 5-LOX was the potential target of HOEC.
Extensive validation ofthe potential HOEC target
Having identified 5-LOX as a specific binding protein of HOEC, we sought to explore the pharmacologic effect of HOEC on 5-LOX. At pure enzyme level, HOEC inhibited 5-LOX activity in vitro with an IC so of 34.6±5.7 11M. Moreover, its effects on 15-LOX, LTA 4H, COX-l and COX-2, the key enzymes in the AA pathway, were also determined. As shown in Fig. 5A , HOEC strongly inhibited 15-LOX with an IC so of7.8±O.8 11M, whereas it showed no inhibition of LTA 4H or COX-I/2 enzymes (data not shown). Nordihydroguaiaretic acid, a reference drug, exhibited potent inhibition of 5-and 15-LOX, the IC so values were 6.8±O.7 11M and 3.4±O.5 11M, respectively.
To further validate the effects of HOEC, the production of AA metabolites was monitored using mass spectrometry III HOEC-treated rat peritoneal macrophages. HOEC markedly inhibited the biosynthesis of LTB 4 and 5-HETE in a concentration-dependent manner (IC so = 8.0±O.7 and 9.7±1.1 11M, respectively). Moreover, it showed moderate inhibition of 8-HETE, but no effect on PGE 2 , 15-HETE or 12-HHT. Meanwhile, slightly or moderately increased 11-and 12-HETE were observed (Fig. 5B ). Zileuton was used as a positive control, and showed potent inhibition of the production of LTB 4 , 5-and 12-HETE, whereas it displayed weak or no effects on production of the L.LIETAL.
TXB2~·HETE
LTB4~~~:~õ 6 .2~2~100 other tested metabolites. In addition, the data from human whole blood revealed that LTB 4 and PGE 2 levels were dramatically increased in response to A23187 stimulation (Fig. 5C ). HOEC was a more potent inhibitor of LTB4 production (IC so = 2.8±0.25 ulvl) in whole blood than in rat macrophages. Zileuton decreased the production of LTB4 with an IC so approximately 0.5±0.08 )lM, which is in agreement with the values reported previously (10) . In contrast, no decrease in the PGE 21e vel. To further understand the pharmacologic effects of HOEC on the AA metabolic network, the dynamic propertie s of the AA metabolic network were studied using an established mathematical model (23) (24) . The current study focused on five enzymes and six metabolites based on their biological significance. Concentration curves of the six metabolites (LTB 4 , 5, 12, I5-H ETE, PGE 2 , TXB) in the model were fitted and compared to the curves resulting from macrophages (Fig. 6A) . The corresponding activity of HOEC on each of the enzymes was calculated based on the best-fit concentration curves. As shown in Fig. 6B , the inhibition intensity of HOEC on IS-LOX was approximately S-fold higher than on S-LOX. However, no inhibition of LTA 4H , COX-I or COX-2 was obtained. The resulting activities were in agreement with those obtained from pure enzyme-based experiments.
In vivo effec ts on inflamm ation models An -induced acute ear oede ma
Having preliminarily identified and validated S-LOX as the potential target of HOEC in vitro and ex vivo, we sought to obtain more evidence regarding HOEC activity in vivo. As shown in Fig.  7A , topical application of AA caused a significant oedema, accompanied by an increase in the vascular permeability and LTB 4 level in ear tissue. Topical treatment with HOEC markedly inhibits the extent of oedema (66.5±5.7%, p < 0.001) and dye permeability (57.5±0.8%, p < 0.001) at 5 mg/ear (Fig. 7A ). LTB 4 production was drastically suppressed by HOEC and reached a maximum inhibition of 82.3±11.2% (p < 0.001) at 5 mg/ear (Fig. 7A) . Additionally, the positive control, dexamethasone (DXT, 0.5 mg/ear), presented a marked inhibition (52.18±7.24%, p < 0.00 I) on ear oedema, and moderately suppressed the increase of dye exudation and LTB 4 level by 33.9±6.24% (p < 0.05) and 30.1±3.25% (p < 0.05), respectively. These results indicate that topical administration ofHOEC exerted protective effects on AA-induced acute inflammation through controlling the excessive production ofLTB 4 •
OVA-induced lung irflammation
An OVA-induced mouse lung inflammation model was used to determine the effect of HOEC on chronic allergic lung inflammation. Bronchoalveolar lavage (BAL) fluid cell counts, BAL fluid LTB 4 concentration, and plasma IgE levels were monitored. As shown in Fig. 7Bi , HOEC treatment (l mg/kg, i.p.) significantly reduced the elevated BAL fluid total cell counts by 48.9±4.7% (p < 0.001). LTB 4 , an important AA metabolite in asthma, was markedly increased after an OVA challenge. The elevated LTB 4 concentration was significantly suppressed by HOEC with inhibition of 94.7±5.2% (p < 0.001) at 1 mg/kg and 79.2±8.6% at 0.2 mg/kg (p < 0.00 I). In addition, no significant decrease in plasma IgE level was observed with HOEC treatment (Fig. 7Bi ). Zileuton was found to significantly inhibit the BAL cell number and BAL LTB 41evei (p < 0.001), and moderately reduce the plasma IgE level. These findings demonstrated the anti-inflammatory effect ofHOEC in chronic lung inflammation, which was subsequently confirmed by histopathologycal examination. As shown in Fig. 7Bii , HOEC could ameliorate OVA-induced lumen narrowing and bronchial thickness, which may result from the hypertrophy ofepithelial cells, bronchial smooth muscle hyperplasia and collagen deposition (28) .
Collagen-induced arthritis (CIA)
A collagen-induced rheumatoid arthritis model was applied to further investigate the effects of HOEC. After type-II collagen (CII) immunisation, the first sign of CIA onset was between days I I and 13. HOEC treatment (l mg/kg, i.p.) moderately decreased the clinical scoring and incidence of CIA (Fig. 8A ). Representative pictures of rat legs also showed that HOEC treatment ameliorated the extent of swelling in CIA (Fig. 8E ). A similar efficacy was observed with Zileuton treatment (l0 mg/kg, i.g.). These results indicate that HOEC moderately decreased the severity and incidence of CIA.
Biochemical detection revealed that LTB 4 and PGE 2 levels in the joints were greatly augmented after cn immunisation, but that their levels in the plasma were not altered. Notably, HOEC (1 mg/kg, i.p.) profoundly reduced the elevated LTB 41evels in the plasma and joint with inhibitions of 45.8±2.6% (p < 0.001) and 50.7±8.3% (p < 0.05), respectively.
In contrast, PGE 21eveis were not affected by HOEC ( Fig. 8, B and C). Real-time PCR and western blotting analysis demonstrated that 5-LOX mRNA and protein expression in the joints was moderately reduced by HOEC treatment (Fig. 8D) . Moreover, anti-CII antibodies in the plasma, including IgM, IgG 1, IgG2a, and IgG2b, markedly increased after cn immunisation approximately 3.3, 3.6, 5.6 and 4.1-fold, respectively. However, no significant inhibition was observed after HOEC treatment.
H&E staining revealed that CIA treatment caused serious cartilage damage, synovium proliferation and bone erosion in joint sections. Further micro-CT analysis showed substantial bone destruction in CIA rats, including severe bone pitting and fusion. All of the pathological changes were ameliorated by HOEC treatment (Fig. 8, F and G) . The findings confirmed the anti-5-LOX activity of HOEC and demonstrated its amelioration of the disease symptoms of CIA.
Toxicity studies
No apparent induction of apoptosis or necrosis in macrophages was observed for HOEC even at concentrations of up to 100 11M. During the above three in vivo animal experiments, no death or apparent abnormal behaviour was observed in HOEC or Zileuton-treated animals. In addition, body weight traces revealed that therapeutic dosages of HOEC and Zileuton had no significant effects on the body weight of the animals (data not shown). Comparison of the long-term toxicity ofHOEC with Zileuton will be pursued in future work.
DISCUSSION
Target identification and validation is the key step in drug discovery and is costly and timeconsuming. There is an ever-increasing demand for effective approaches to find the targets of bioactive natural products and elucidate the mechanisms by which they affect disease progression. This study employed a reliable chemical biology strategy to successfully identify and validate the target of a natural product, HOEC. This work clarified the potential anti-inflammatory mechanism of HOEC. Using a pull-down assay, HOEC was found to bind to 5-LOX, which is a protein involved in the pathogenesis of inflammation. Next, a biosensorbased biomolecular interaction analysis also clearly determined that 5-LOX was specifically bound to HOEC. Taken together, the pull-down assay and the biosensor-based analysis suggested that 5-LOX was the potential target of HOEC. These data provided a promising starting point and provoked our interest for further study.
Having identified 5-LOX as the potential target of HOEC, we sought to obtain more evidence and attempt to explore the pharmacologic effects of HOEC on 5-LOX by extensive validation studies. Our results revealed that HOEC not only inhibited pure 5-LOX but also reduced 5-LOX-derived metabolites in rat peritoneal macrophages, which is inflammatory cell type process either complete LOX or COX pathway of AA cascade (30) . These results supported our previous hypothesis that 5-LOX was the potential target of HOEC. Subsequently, human whole blood was used because it is a more reliable evaluation system, as it is composed of erythrocytes, platelets and various leukocytes. This mimics the in vivo microenvironment and can be used as a good transcellular metabolic system for drug evaluation (31) . There is accumulating evidence supporting the significance of the transcellular biosynthetic pathway of eicosanoids in inflammation (30) (31) . The identification of 5-LOX as the target of HOEC was extensively validated by data from pure enzyme assays, single cell systems and transcellular systems, and HOEC was proven to be a potent and specific 5-LOX inhibitor in vitro and ex vivo.
Interestingly, the effect of HOEC on pure 15-HETE in macrophages seems inconsistent with the results from the experiment using pure 15-LOX. This discrepancy can be explained from a systems biology perspective, and occurs due to complex interactions and feedback regulations (23) . Computer-aided dynamic simulation of the AA metabolic network in the current work integrated the data from pure enzymatic assays with those from cells that had a complicated AA network, which was in agreement with the report by Yang, et al. Notably, the simulation indicated that the production of LTs decreased with the concomitant increase of exogenous AA due to the negative-feedback mechanisms in the 5-LOX pathway, and that the output of 15-HETE increased at the same time as a decrease in LTs. Thus, the simulation predictions are qualitatively consistent with the experimental results. In other words, these results explained the above-mentioned discrepancy as being due to the existence of the complicated AA metabolic network in macrophages. The effect of HOEC in a pure enzyme activity assay was not the same as its effect in the intact cell system, which furthered the understanding of the pharmacologic effects ofHOEC and implemented new thinking drug discovery from a biological network perspective. In a complex biological system, drug molecules usually not only interact with one specific target but also alter the state and function of the associated biological network (23) . Considering the crosstalk between biological responses rather than examining single response may provide a better understanding of disease development and achieve accurate evaluation of drug efficacy.
Moreover, 15-LOX-derived 15-HETE biological activity is still unclear. Some studies reported that it exerted pro-inflammatory effects by enhancing vascular permeability. However, there is also a broad line ofevidence that 15-HETE has anti-inflammatory effects and that it could present protective roles in inflammatory disorders by reducing synovitis through decreased LTB4 production in experimental arthritis, inhibiting chemotaxis of neutrophils to LTB 4 or through transcellular formation of anti-inflammatory lipoxins (32) (33) . In this sense, it is reasonable that 5-LOX but not 15-LOX was identified as the key anti-inflammatory target of HOEC.
Finally, the in vivo potency of HOEC and the key role of 5-LOX were thoroughly demonstrated in three different types of inflammation: AAinduced acute ear oedema, OVA-induced mouse lung inflammation and collagen-induced arthritis (CIA). AA-induced mouse ear oedema, which is due to the formation of AA metabolites, mainly LTB 4 , provides a direct and rapid measurement of drug potency on AA cascade-related acute inflammation in vivo. OVA-induced mouse lung inflammation is a type of chronic allergic inflammation, which has known to be closely tied to 5-LOX activity. CIA is a widely used model of RA and has been important for understanding autoimmune inflammation. The findings were supported by numerous animal experiments, including 5-LOX and FLAP-deficient animal models, which, have demonstrated the contribution of LTs to inflammation (16, 34) . The effect of HOEC on CIA will be addressed in future studies.
In conclusion, the present study demonstrated that HOEC is an anti-inflammatory agent that targets 5-LOX, which provided new evidence regarding the role of 5-LOX in various inflammatory diseases. Importantly, it provided a promising and rational paradigm for target identification and mechanism of action research for small molecules, which will boost the application of chemical biological approaches in drug research.
